This medical technology company supplies single-use devices for critical care and surgery to hospitals and healthcare providers worldwide.

Teleflex’s TFX Interventional Urology portfolio is well positioned for sustained growth, led by UroLift’s expanding global footprint and strong clinical differentiation. Supported by favorable ...

Teleflex's TFX robust performance in the Interventional product line is poised to help it grow in the upcoming quarters. The Urolift system is seeing consistent growth in hospitals, with positive ...

Teleflex (NYSE:TFX) is slated for expansion in the coming quarters, owing to the key growth drivers in the Interventional business. The company's market dominance in Central Venous Catheters and ...

The stock's fall snapped a four-day winning streak.

Teleflex (NYSE:TFX – Free Report) had its price objective lowered by Mizuho from $150.00 to $130.00 in a research report released on Wednesday,Benzinga reports. The brokerage currently has a neutral ...

What recent performance says about Teleflex Teleflex (TFX) has drawn attention after a mixed stretch, with the stock up about ...

On August 1, Teleflex will release earnings for the most recent quarter. Analysts on Wall Street expect Teleflex will release earnings per share of $3.33. Track Teleflex stock price in real-time on ...

Teleflex (NYSE:TFX – Get Free Report) was downgraded by research analysts at Raymond James from an “outperform” rating to a “market perform” rating in a report released on Friday, Marketbeat reports.

The latest announcement is out from Teleflex ( (TFX) ).